FDG-PET Staging and Importance of Lymph Node SUV in Head and Neck Cancer

Overview

Journal Head Neck Oncol

Specialty Oncology

Date 2010 Jul 20

PMID 20637102

Citations 35

Authors

Gregory J Kubicek

Collin Champ

Shannon Fogh

Fen Wang

Eashwer Reddy

Charles Intenzo

Reginald W Dusing

Mitchell Machtay

Affiliations

Soon will be listed here.

Abstract

Objectives: The role of positron emission tomography (PET) with fluoro-deoxy-glucose (FDG) in the staging of head and neck cancer (HNC) is unclear. The NCCN guidelines do not recommend FDG-PET as a part of standard workup. The purpose of this report is to examine the role of FDG-PET imaging in altering management and providing prognostic information for HNC.

Methods: Retrospective review of HNC patients who had a staging FDG-PET scan performed at either Thomas Jefferson University or University of Kansas Medical Center between the years 2001 and 2007. A total of 212 PET scans were performed in patients who went on to receive radiotherapy.

Results: The median follow-up time for all patients was 469 days. The PPV and NPV of PET imaging to correctly identify lymph node status was 94% and 89% respectively. Lymph nodes with extracapsular extension (ECE) had higher SUVs than nodes without ECE, 11.0 vs. 5.0 (p < 0.0007). Maximum SUV for the primary tumor > 8.0 was predictive of worse overall survival (p < 0.045), while the SUV of the lymph nodes was predictive for distant recurrence at one year--with a mean SUV value of 10.4 for patients with distant failure vs. 7.0 without (p < 0.05).

Conclusions: FDG-PET staging in head and neck cancer has good positive and negative predictive values in determining lymph node status. The maximum SUV of the primary tumor is predictive of overall survival. This is the first report to find that the SUV of a lymph node is predictive for ECE and also for distant recurrence.

Citing Articles

Role of the FDG PET CT Scan in Pretreatment Evaluation of Oral Carcinomas.

Banjare A, Arora R, Ravina M, Prajwal S, Rao K, Nagarkar N Indian J Otolaryngol Head Neck Surg. 2024; 76(6):5346-5352.

PMID: 39559068 PMC: 11569347. DOI: 10.1007/s12070-024-04974-4.

From FDG and beyond: the evolving potential of nuclear medicine.

Hirata K, Kamagata K, Ueda D, Yanagawa M, Kawamura M, Nakaura T Ann Nucl Med. 2023; 37(11):583-595.

PMID: 37749301 DOI: 10.1007/s12149-023-01865-6.

Role of F-FDG PET/CT in Guiding Surgical Management of Clinically Node Negative Neck (cN0) in Carcinoma Oral Cavity.

Vartak A, Malhotra M, Jaiswal P, Talwar R, Tyagi A, Kishore B Indian J Otolaryngol Head Neck Surg. 2023; 75(3):1799-1805.

PMID: 37636652 PMC: 10447354. DOI: 10.1007/s12070-023-03744-y.

Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial.

Kann B, Likitlersuang J, Bontempi D, Ye Z, Aneja S, Bakst R Lancet Digit Health. 2023; 5(6):e360-e369.

PMID: 37087370 PMC: 10245380. DOI: 10.1016/S2589-7500(23)00046-8.

Prediction of extranodal extension in oropharyngeal cancer patients and carcinoma of unknown primary: value of metabolic tumor imaging with hybrid PET compared with MRI and CT.

Nemmour A, Stadler T, Maurer A, Kovacs Z, Serrallach B, Born D Eur Arch Otorhinolaryngol. 2022; 280(4):1973-1981.

PMID: 36471046 DOI: 10.1007/s00405-022-07765-1.

References

Bernier J, Cooper J, Pajak T, Van Glabbeke M, Bourhis J, Forastiere A . Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005; 27(10):843-50. DOI: 10.1002/hed.20279. View

Kyzas P, Evangelou E, Denaxa-Kyza D, Ioannidis J . 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst. 2008; 100(10):712-20. DOI: 10.1093/jnci/djn125. View

Murakami R, Uozumi H, Hirai T, Nishimura R, Shiraishi S, Ota K . Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2007; 68(2):377-82. DOI: 10.1016/j.ijrobp.2006.12.032. View

Schwartz D, Rajendran J, Yueh B, Coltrera M, LeBlanc M, Eary J . FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg. 2004; 130(12):1361-7. DOI: 10.1001/archotol.130.12.1361. View

Greven K, Williams 3rd D, McGuirt Sr W, Harkness B, DAgostino Jr R, Keyes Jr J . Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2002; 23(11):942-6. DOI: 10.1002/hed.1136. View

Stoeckli S, Steinert H, Pfaltz M, Schmid S . Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck. 2002; 24(4):345-9. DOI: 10.1002/hed.10057. View

Minn H, Lapela M, Klemi P, Grenman R, Leskinen S, Lindholm P . Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1998; 38(12):1907-11. View

Halfpenny W, Hain S, Biassoni L, Maisey M, Sherman J, McGurk M . FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002; 86(4):512-6. PMC: 2375291. DOI: 10.1038/sj.bjc.6600114. View

Fleming Jr A, Smith Jr S, Paul C, Hall N, Daly B, Agrawal A . Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope. 2007; 117(7):1173-9. DOI: 10.1097/MLG.0b013e31805d017b. View

10.

Schwartz D, Ford E, Rajendran J, Yueh B, Coltrera M, Virgin J . FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2005; 61(1):129-36. DOI: 10.1016/j.ijrobp.2004.03.040. View

11.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

12.

Yen T, Chang J, Ng S, Chang Y, Chan S, Lin K . The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med. 2005; 46(3):405-10. View

13.

Machtay M, Moughan J, Trotti A, Garden A, Weber R, Cooper J . Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008; 26(21):3582-9. PMC: 4911537. DOI: 10.1200/JCO.2007.14.8841. View

14.

Ng S, Yen T, Chang J, Chan S, Ko S, Wang H . Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol. 2006; 24(27):4371-6. DOI: 10.1200/JCO.2006.05.7349. View

15.

Endo K, Oriuchi N, Higuchi T, Iida Y, Hanaoka H, Miyakubo M . PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol. 2006; 11(4):286-96. DOI: 10.1007/s10147-006-0595-0. View

16.

Vermorken J, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M . Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357(17):1695-704. DOI: 10.1056/NEJMoa071028. View

17.

Allal A, Slosman D, Kebdani T, Allaoua M, Lehmann W, Dulguerov P . Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004; 59(5):1295-300. DOI: 10.1016/j.ijrobp.2003.12.039. View

18.

Roh J, Pae K, Choi S, Kim J, Lee S, Kim S . 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol. 2007; 33(6):790-5. DOI: 10.1016/j.ejso.2007.01.002. View

19.

Posner M, Hershock D, Blajman C, Mickiewicz E, Winquist E, Gorbounova V . Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357(17):1705-15. DOI: 10.1056/NEJMoa070956. View

20.

Brun E, Kjellen E, Tennvall J, Ohlsson T, Sandell A, Perfekt R . FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002; 24(2):127-35. DOI: 10.1002/hed.10037. View